Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Status:
Withdrawn
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and disease control rate of the combination of
pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or
renal cell cancer.